Background: Reduced bone mineral density (BMD) is a frequent comorbidity observedin people living with HIV (PLHIV). Objective: The aim of the study is to determine the prevalence and associated factors of reducedbone mineral density (BMD) among men with suppressed viral load taking antiretroviral therapy. Methods: The study was conducted as a cross-sectional design between January to April 2019. 211patients were included in the study. Z-score at either body site between -1.0 and -2.0 or -2 or lesswas defined as osteopenia or osteoporosis, respectively. Multivariate logistic regression analysiswas used to evaluate the factors affecting the development of reduced BMD. Results: The mean age of the patients involved in the study was 34.8 ± 7.6. Osteoporosis was detectedin 21.4% and osteopenia in 44.5% of the patients. There was a significant relationship foundbetween HIV diagnosis time, ART usage duration, tenofovir disoproxil fumarate (TDF) use, TDFuse in the past, total TDF usage time and decreased BMD. Multivariate logistic regression analysisshowed that the likelihood of reduced bone marrow density was 67% lower among those with regularmilk or dairy product intake compared to those without (OR=0.330; 95% CI = 0.12-0.92,p=0.033). Conclusion: There is a high prevalence of reduced BMD among PLHIV aged under 50, which ismainly confounded by HIV diagnosis time, ART usage duration and TDF usage. Although virologicalcontrol has been achieved, these patients should be followed up, considering that they mayhave decreased BMD.